Sanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMS
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – French drug major Sanofi (SNYNF, SNY) announced Monday that its oral brain-penetrant Bruton’s tyrosine kinase or BTK inhibitor Tolebrutinib, in the HERCULES phase 3 study, met the primary endpoint in delaying time to onset of confirmed disability progression in people
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-89739213-33fa62bb8fd14c5b98e1ae20e7c0b58b.jpg "3 Surprising Stocks That Have Outperformed Big Names in the Last 10 Years")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1632178785-2bbf98c928b749329959617a646e8bf8.jpg "How WhatsApp Makes Money")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1132012708-0d3f8f4b04c14405aa72e54940ab6a0e-3064dc565912458a94297c60b3d609e7.jpg "Is a Career in Investment Banking Worth It?")
:max_bytes(150000):strip_icc():format(jpeg)/KraftCadburyHostileTakeover-56143341d0004032a1cdb65ec3c2859b.jpg "What Are Some Top Examples of Hostile Takeovers?")
